SK Biopharmaceuticals inks $58 million deal for pain treatment drug
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
![SK Biopharmaceuticals CEO Lee Dong-hoon speaks during the 42nd J.P. Morgan Healthcare Conference in San Francisco, California, in January. [SK BIOPHARM]](https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202404/18/koreajoongangdaily/20240418173308639rjgl.jpg)
SK Biopharmaceuticals inked a technology transfer deal worth up to $58 million with Shanghai, China-based Ignis Therapeutics for a nonnarcotic pain treatment candidate.
The deal grants Ignis Therapeutics exclusive rights to develop and market the candidate, named SKL22544, globally.
The size of the deal is potentially $58 million, including a $3 million upfront payment, up to $55 million in milestone payments and additional royalties based on the drug’s future sales.
SK Biopharmaceuticals is also empowered to repurchase the rights to the U.S. market until the candidate's efficacy is confirmed. The right for the Korean market could be transferred to SK in the future.
BY SARAH CHEA [chea.sarah@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Yellow dust blankets Korea as warnings to 'stay indoors' are issued
- ‘Our best performance’: Le Sserafim’s Sakura defends divisive Coachella debut
- BTS pop-up store to open in Seoul's Seongsu-dong area
- Festival with Japanese adult entertainers relocates again after Seoul gov't warns venue
- Seoul Station train collision involving KTX, 287 passengers transferred
- Younger Koreans more willing to have children, survey says
- Most foreigners in Korea earn 2 to 3 million won a month, report says
- Finance chiefs of Korea, U.S., Japan recognize concerns over slumping currencies
- BabyMonster steps into YG's Blackpink vacuum
- Korea and Japan pledge joint action on exchange rate free fall